AU2018327301B2 - Formulation of resiniferatoxin - Google Patents

Formulation of resiniferatoxin Download PDF

Info

Publication number
AU2018327301B2
AU2018327301B2 AU2018327301A AU2018327301A AU2018327301B2 AU 2018327301 B2 AU2018327301 B2 AU 2018327301B2 AU 2018327301 A AU2018327301 A AU 2018327301A AU 2018327301 A AU2018327301 A AU 2018327301A AU 2018327301 B2 AU2018327301 B2 AU 2018327301B2
Authority
AU
Australia
Prior art keywords
rtx
formulation
formulations
polysorbate
phosphate buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018327301A
Other languages
English (en)
Other versions
AU2018327301A1 (en
Inventor
Bryan Jones
Alexis Nahama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivasor Inc
Original Assignee
Vivasor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivasor Inc filed Critical Vivasor Inc
Publication of AU2018327301A1 publication Critical patent/AU2018327301A1/en
Assigned to VIVASOR, INC. reassignment VIVASOR, INC. Request for Assignment Assignors: SORRENTO THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2018327301B2 publication Critical patent/AU2018327301B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018327301A 2017-09-11 2018-09-11 Formulation of resiniferatoxin Ceased AU2018327301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556824P 2017-09-11 2017-09-11
US62/556,824 2017-09-11
PCT/IB2018/056944 WO2019049112A1 (en) 2017-09-11 2018-09-11 RESINIFERATOXIN FORMULATION

Publications (2)

Publication Number Publication Date
AU2018327301A1 AU2018327301A1 (en) 2020-04-09
AU2018327301B2 true AU2018327301B2 (en) 2024-08-22

Family

ID=63708422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018327301A Ceased AU2018327301B2 (en) 2017-09-11 2018-09-11 Formulation of resiniferatoxin

Country Status (9)

Country Link
US (3) US20190076396A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681472A1 (cg-RX-API-DMAC7.html)
JP (2) JP7358337B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200051771A (cg-RX-API-DMAC7.html)
CN (1) CN111315360B (cg-RX-API-DMAC7.html)
AU (1) AU2018327301B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074951A1 (cg-RX-API-DMAC7.html)
MX (2) MX2020002692A (cg-RX-API-DMAC7.html)
WO (1) WO2019049112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020226370A1 (ko) 2019-05-09 2020-11-12 주식회사 엘지화학 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
US20230143545A1 (en) * 2020-03-30 2023-05-11 Board Of Regents Of The University Of Nebraska Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
WO2021257956A1 (en) * 2020-06-19 2021-12-23 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of bladder pain or bladder cancer
EP4291174A1 (en) * 2021-02-11 2023-12-20 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of prostate cancer
US20250228765A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019436A1 (en) * 2002-12-18 2005-01-27 Algorx Injectable capsaicin
US20100196281A1 (en) * 2004-12-28 2010-08-05 Mestex Ag Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
ES2384244T3 (es) * 2004-12-28 2012-07-02 Mestex Ag Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN113490745A (zh) * 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) * 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019436A1 (en) * 2002-12-18 2005-01-27 Algorx Injectable capsaicin
US20100196281A1 (en) * 2004-12-28 2010-08-05 Mestex Ag Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GABRIEL C TENDER ET AL: "Selective ablation of nociceptive neurons for elimination of hyperalgesia and neurogenic inflammation", NEUROSURGICAL FOCUS, May 2005 (2005-05-01), pages 1 - 5, XP055533023. *
KARAI L ET AL: "Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 113, no. 9, January 2004 (2004-01-01), pages 1344 - 1352. *

Also Published As

Publication number Publication date
KR20200051771A (ko) 2020-05-13
US20220370405A1 (en) 2022-11-24
AU2018327301A1 (en) 2020-04-09
CN111315360B (zh) 2025-01-17
CA3074951A1 (en) 2019-03-14
MX2020002692A (es) 2020-10-14
MX2022013947A (es) 2022-11-30
JP2020533336A (ja) 2020-11-19
EP3681472A1 (en) 2020-07-22
JP7358337B2 (ja) 2023-10-10
WO2019049112A1 (en) 2019-03-14
US20250000842A1 (en) 2025-01-02
JP2022176377A (ja) 2022-11-25
CN111315360A (zh) 2020-06-19
US20190076396A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
US20250000842A1 (en) Formulation of Resiniferatoxin
ES2640572T3 (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas
DE69808695T2 (de) Stabile Insulinformulierungen
KR101593579B1 (ko) 치료용 조성물
DE3686221T2 (de) Emulsionen zur parenteralen und/oder oralen verabreichung schwer wasserloeslicher ionisierbarer hydrophober arzneistoffe.
DE69507493T2 (de) Tirilazad parentale formulierung mit einem co-lösungsmittel
DE69621942T2 (de) Verbessertes herstellungsverfahren und zusammensetzung für therapeutisches cisplatin (cddp)
DE69832375T2 (de) Verwendungsmethoden makrocyklischer lactonverbindungen als mittel zur umkehr der mehrfach-arzneimittelresistenz in tumor-und anderen zellen
CN101959501B (zh) 稳定的含多西紫杉醇的单液药用组合物
JP5847722B2 (ja) pH調節剤を含むタキサンの医薬溶液、およびその作製方法
DE10355251A1 (de) Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2016028968A1 (en) Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions
JP2018515484A (ja) カバジタキセル脂肪乳剤注射剤、その調製方法およびその使用
UA123312C2 (uk) Спосіб поліпшення розчинності у воді нерозчинних або малорозчинних у воді лікарських засобів
KR20110009128A (ko) 미세소관-상호작용 제제를 위한 지질-오일-물 나노에멀젼 전달 시스템
RU2613490C2 (ru) Композиция на основе R(-)-празиквантела для лечения и профилактики гельминтозов у теплокровных
DE4312016A1 (de) Stabile Ketamin-Lösungen
CN101322688B (zh) 供静脉用氟马西尼的水包油乳剂及制备方法
RU2712264C2 (ru) Состав для инъекций на основе силибина и способ его получения
DE60122384T2 (de) Verfahren zur herstellung einer beständige pharmazeutische form von paclitaxel
CN104771360B (zh) 一种蒿甲醚纳米乳药物组合物及其制备方法
CN116077416B (zh) 一种包含孕激素的口服制剂及制备方法和应用
BR102021002197A2 (pt) Método de tratamento, uso e composição veterinária injetável tixotrópica para liberação controlada de doramectina e vitamina e
Harder et al. Pharmacokinetics of orally administered calcium dobesilate in Warmblood horses
TWI246927B (en) One kind of concentrated emulsion containing Paclitaxel (taxane)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VIVASOR, INC.

Free format text: FORMER APPLICANT(S): SORRENTO THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired